LYON, France, September 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference and the H.C. Wainwright 25th Annual Global Investment Conference, both being held September 11-13, 2023, in New York City.
H.C. Wainwright presentation details:
| Date: | Tuesday, September 12 |
| Time: | 4:30 PM - 5:00 PM ET |
Morgan Stanley presentation details:
| Date: | Wednesday, September 13 |
| Time: | 7:30 AM - 8:00 AM ET |
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.
| Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Contact John Fraunces LifeSci Advisors, LLC (917) 355-2395 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$2.14 |
| Daily Change: | -0.03 -1.38 |
| Daily Volume: | 22,689 |
| Market Cap: | US$80.010M |
October 20, 2025 September 08, 2025 August 28, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
